Novartis’ board faces investor scrutiny after M&A misfires and R&D flops

negativeNegative

AI Analysis

Summary

Novartis' board faces investor scrutiny following back-to-back failures of multiple late-phase trials and M&A missteps, raising questions about the company's capital deployment strategy for growth through the 2030s.

Outcome Details

Back-to-back failures of multiple late-phase trials

Importance:6/10

Sentiment:

-0.70

R&Dlate-phase trial failurescapital deploymentM&A strategygovernance

Related Companies

$NVS

Read the original article

Published by BioSpace on September 11, 2026 4:01 AM

Read Original